上市后藥物的經濟學評價_《中國循證醫學雜志》

作者：

胡善聯

復旦大學公共衛生學院,上海,200032;

關鍵詞：

循證藥物評價上市后評價藥物經濟學

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

本文重點討論了藥物經濟學的特征和常用的評價方法.藥品上市后為大量臨床實踐提供了觀察治療效果和不良反應監測的機會.上市后藥品的經濟學評價方法除了常用的成本效果分析方法以外,還注重于效益風險分析、藥品列入報銷目錄的申請、藥品的補償和預算影響分析等.

引用本文： 胡善聯. 上市后藥物的經濟學評價. 中國循證醫學雜志, 2005, 05(5): 353-356. doi: 復制

1.	李廷謙, 王剛, 王蕾. 循證醫學與中藥上市后的再評價[J]. 中國循證醫學雜志, 2004; 4(4): 217～221.
2.	胡大一, 楊進剛. 應重視上市后藥物安全性的循證醫學再評價--羅非昔布召回的意義[J]. 中國循證醫學雜志, 2005; 5(2): 94～96.
3.	Li TQ, Wang G, Wang L. Evidence-based medicine and reassessment of post-marketed Chinese herbs[J]. Chinese Journal of Evidence-based Medicine, 2004; 4(4): 217-221.
4.	Farley Dixie. Benefit vs. Risk: How FDA Approves New Drugs [EB/OL]. FDA Consumer Special Report. 1995 Jan. Available from: URL: http://www.fda.gov/fdac/special/new drug/benefits.html.
5.	Langley PC. Pharmacoeconomics in Drug Development and Marketing: An Overview. ISPOR Distance Learning Program. Monograph. 2004.
6.	Langley PC. Pharmacoeconomics in Market Entry and Market Support. ISPOR Distance Learning Program. Monograph. 2004.
7.	Hu DY, Yang JG. Evidence-Based safety reassessment of post-marketed drug-important of recall of Refecoxib[J]. Chinese Journal of Evidence-based Medicine, 2005; 5(2): 94-96.
8.	Barden J, Edwards JE, McQuay HJ, Moore RA. Single Dose Oral Celecoxib for Postopreative Pain (Cochrane Reviw). In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd.
9.	Barden J, Edwards J, Moore RA, McQuay HJ. Single Dose Oral Rofecoxib for Postoperative Pain (Cochrane Reviw). In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd.
10.	Jackson CM, Lipworth B. Benefit-risk assessment of long-acting beta2-agonists in asthma[J]. Drug Saf, 2004; 27(4): 243-270.

1. 李廷謙, 王剛, 王蕾. 循證醫學與中藥上市后的再評價[J]. 中國循證醫學雜志, 2004; 4(4): 217～221.
2. 胡大一, 楊進剛. 應重視上市后藥物安全性的循證醫學再評價--羅非昔布召回的意義[J]. 中國循證醫學雜志, 2005; 5(2): 94～96.
3. Li TQ, Wang G, Wang L. Evidence-based medicine and reassessment of post-marketed Chinese herbs[J]. Chinese Journal of Evidence-based Medicine, 2004; 4(4): 217-221.
4. Farley Dixie. Benefit vs. Risk: How FDA Approves New Drugs [EB/OL]. FDA Consumer Special Report. 1995 Jan. Available from: URL: http://www.fda.gov/fdac/special/new drug/benefits.html.
5. Langley PC. Pharmacoeconomics in Drug Development and Marketing: An Overview. ISPOR Distance Learning Program. Monograph. 2004.
6. Langley PC. Pharmacoeconomics in Market Entry and Market Support. ISPOR Distance Learning Program. Monograph. 2004.
7. Hu DY, Yang JG. Evidence-Based safety reassessment of post-marketed drug-important of recall of Refecoxib[J]. Chinese Journal of Evidence-based Medicine, 2005; 5(2): 94-96.
8. Barden J, Edwards JE, McQuay HJ, Moore RA. Single Dose Oral Celecoxib for Postopreative Pain (Cochrane Reviw). In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd.
9. Barden J, Edwards J, Moore RA, McQuay HJ. Single Dose Oral Rofecoxib for Postoperative Pain (Cochrane Reviw). In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd.
10. Jackson CM, Lipworth B. Benefit-risk assessment of long-acting beta2-agonists in asthma[J]. Drug Saf, 2004; 27(4): 243-270.

《中國循證醫學雜志》

上市后藥物的經濟學評價

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國循證醫學雜志》

上市后藥物的經濟學評價

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料